CryoPort (NASDAQ:CYRX) Shares Gap Up on Analyst Upgrade

Key Points

• Shares jumped after analyst upgrades: CryoPort stock gapped up following Guggenheim's upgrade and higher targets from BTIG, Needham and others, trading up about 19.3% to roughly $12.37 with a consensus "Moderate Buy" average target of $14.44.
• Mixed fundamentals: Q1 revenue beat and management raised FY2026 revenue guidance to $192–$196M with commercial CGT revenue up 26% YoY, but the company missed EPS expectations (loss $0.23) and remains unprofitable with negative return on equity.
• Insider selling and concentrated ownership: Company insiders sold shares in March (59,939 shares sold in the last quarter) while institutional investors own about 92.9% of the stock, which may influence liquidity and market sentiment.

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report)'s stock price gapped up before the market opened on Tuesday after Guggenheim raised their price target on the stock from $11.00 to $12.00. The stock had previously closed at $10.21, but opened at $11.00. Guggenheim currently has a buy rating on the stock. CryoPort shares last traded at $12.3710, with a volume of 243,974 shares changing hands.

A number of other research firms also recently commented on CYRX. BTIG Research increased their price objective on CryoPort from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Tuesday. Craig Hallum started coverage on CryoPort in a report on Monday, March 30th. They issued a "buy" rating and a $15.00 price objective on the stock. Weiss Ratings restated a "sell (d+)" rating on shares of CryoPort in a report on Friday, March 27th. Needham & Company LLC increased their price objective on CryoPort from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, Wall Street Zen downgraded CryoPort from a "hold" rating to a "sell" rating in a report on Sunday. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $14.44.

Insider Activity

In other news, CEO Jerrell Shelton sold 7,918 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $8.00, for a total transaction of $63,344.00. Following the transaction, the chief executive officer owned 1,054,501 shares of the company's stock, valued at approximately $8,436,008. This represents a 0.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Mark W. Sawicki sold 3,235 shares of the stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $25,880.00. Following the transaction, the insider directly owned 103,697 shares in the company, valued at approximately $829,576. This represents a 3.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 59,939 shares of company stock valued at $471,183. Insiders own 10.00% of the company's stock.

CryoPort News Roundup

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Two brokerages raised ratings/targets today — BTIG bumped its target to $17 (buy) and Needham raised its target to $15 (buy), signaling fresh buy-side conviction and sizable upside vs. the recent share price. Benzinga The Fly
• Positive Sentiment: Q1 revenue of $47.8M topped expectations and grew ~16% year-over-year; management raised FY2026 revenue guidance to $192–$196M, which supports the bullish analyst re-rates. PR Newswire
• Positive Sentiment: Commercial cell & gene therapy (CGT) revenue grew 26% YoY and the company now supports 21 approved CGTs and 766 clinical trials globally — evidence of durable demand in higher-value segments. PR Newswire
• Neutral Sentiment: Full earnings materials (transcript, slide deck) are available for deeper read; investors can use these to vet margin drivers and cadence of CGT revenue. Slide Deck / Press Release Earnings Transcript
• Neutral Sentiment: Company issued revenue guidance but did not provide a clear EPS range in the release, leaving near-term profitability trajectory less certain. PR Newswire
• Negative Sentiment: EPS missed estimates: a $0.23 loss vs. consensus of about a $0.20 loss, and the company remains unprofitable — a reminder that revenue growth hasn’t yet translated into GAAP profitability. Zacks
• Negative Sentiment: Despite the revenue beat, CryoPort still shows a negative return on equity and remains loss-making, which could limit multiple expansion unless profitability improves. MarketBeat

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CYRX. SG Americas Securities LLC grew its holdings in CryoPort by 663.2% in the 3rd quarter. SG Americas Securities LLC now owns 127,280 shares of the company's stock valued at $1,207,000 after buying an additional 110,602 shares during the last quarter. Mak Capital One LLC acquired a new stake in CryoPort in the 3rd quarter valued at approximately $7,756,000. Segall Bryant & Hamill LLC acquired a new stake in CryoPort in the 3rd quarter valued at approximately $652,000. Conestoga Capital Advisors LLC grew its holdings in CryoPort by 52.0% in the 4th quarter. Conestoga Capital Advisors LLC now owns 159,864 shares of the company's stock valued at $1,535,000 after buying an additional 54,675 shares during the last quarter. Finally, Harbor Capital Advisors Inc. acquired a new stake in CryoPort in the 4th quarter valued at approximately $352,000. Institutional investors and hedge funds own 92.90% of the company's stock.

CryoPort Trading Up 19.3%

The stock has a market cap of $611.26 million, a price-to-earnings ratio of 9.23 and a beta of 1.75. The stock has a fifty day simple moving average of $8.92 and a 200-day simple moving average of $9.32.

CryoPort (NASDAQ:CYRX - Get Free Report) last released its earnings results on Tuesday, March 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). The business had revenue of $45.45 million during the quarter, compared to analyst estimates of $42.92 million. CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. Sell-side analysts forecast that CryoPort, Inc. will post -0.73 earnings per share for the current fiscal year.

About CryoPort

CryoPort, Inc NASDAQ: CYRX is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.